Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to invest in a range of small-cap companies because of their great growth potential, the Vanguard Small Cap ETF
ETFs often sport lower expense ratios than their mutual fund cousins. The small-cap ETF's expense ratio -- its annual fee -- is a very low 0.17%.
This ETF has performed reasonably well, but it's also very young, with just a few years on the books. It outperformed the S&P 500, on average, over the past three and five years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.
What's in it?
Plenty of small-cap companies had strong performances over the past year. BioMarin Pharmaceutical
Other companies didn't do as well last year, but they could see their fortunes change in years to come. Senior Housing Properties Trust
The big picture
Small-cap stocks can add diversity and some great growth potential to your portfolio. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.
Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter here, holds no position in any company mentioned. Click here to see her holdings and a short bio. Motley Fool newsletter services have recommended buying shares of ITC Holdings and BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why This Gene Therapy Pioneer Crashed 29.8% in December
Progress toward commercializing its first gene therapy failed to overcome concern about competition last month.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
The biotech keeps plugging along.